ZUG, Switzerland, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS) today announced that it will release its financial results for the second quarter ended June 30, 2014, on Monday, September 15, 2014. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (2:00 p.m. Central European Time) to discuss Auris Medical's financial results for the second quarter and provide a general business update.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.
HUG#1854378
